RT Journal Article
SR Electronic
T1 Heparin therapy improving hypoxia in COVID-19 patients - a case series
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.15.20067017
DO 10.1101/2020.04.15.20067017
A1 Elnara Marcia Negri
A1 Bruna Mamprim Piloto
A1 Luciana Kato Morinaga
A1 Carlos Viana Poyares Jardim
A1 Shari Anne El-Dash Lamy
A1 Marcelo Alves Ferreira
A1 Elbio Antonio D’Amico
A1 Daniel Deheinzelin
YR 2020
UL http://medrxiv.org/content/early/2020/04/22/2020.04.15.20067017.abstract
AB INTRODUCTION Elevated D-dimer is predictor of severity and mortality in COVID-19 patients and heparin use during in hospital stay has been associated to decreased mortality. COVID-19 patient autopsies have revealed thrombi in the microvasculature, suggesting intravascular coagulation as a prominent feature of organ failure in these patients. Interestingly, in COVID-19, pulmonary compliance is preserved despite severe hypoxemia corroborating the hypothesis that perfusion mismatch may play a significant role in the development of respiratory failure.METHODS We describe a series of 27 consecutive COVID-19 patients admitted to the Pulmonology service at Sirio-Libanes Hospital in São Paulo-Brazil treated with heparin in therapeutic doses tailored to clinical severity.RESULTS PaO2/FiO2 ratio increased significantly over the 72 hours following the start of anticoagulation, from 254(±90) to 325(±80), p=0.013, and over half of the patients were discharged home within an average time of 7.3 (±4.0) days. Half of mechanically ventilated patients were extubated within 10.3 (±1.5) days. The remaining patients showed progressive improvement and there were no bleeding complications or fatal events.DISCUSSION Even though this uncontrolled case series does not offer absolute proof of DIC as the underlying mechanism of respiratory failure in COVID-19, as well as patients positive response to tailored dose heparinization, it contributes to the understanding of the physiopathological mechanism of the disease and provides valuable information for the treatment of these very sick patients while we await the results of further prospective controlled studies.Key question Does therapeutical doses of heparin bring benefit in the management of respiratory failure in COVID 19 patients? And is it safe?Bottom line Our results show a significant improvement of hypoxemia in COVID-19 patients treated with early heparin therapy.Why read on?DIC may play a major role in the development of respiratory failure in COVID-19 and anticoagulation could be incorporated in the standard-of-care for these patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis was a retrospective study based on medical records data with no funding needed.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be provided if requested. It contais confidential medical records.